Project Grant K08AI190313
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $423,500 in funding to The Leland Stanford Junior University to conduct research on the use of antimicrobial peptides and antibiotic diffusion in sputum. The key objectives are to investigate how Pseudomonas aeruginosa bacteriophages (PF phages) present in cystic fibrosis patient sputum can inhibit antibiotic diffusion, and to explore the...
- The Stanford University received a $337,147 Project Grant award from the National Institute of Allergy and Infectious Diseases to develop an immunization against Pseudomonas aeruginosa infection. The grant supports research to evaluate the effectiveness of antibodies against bacteriophage PF in promoting phagocytosis and clearance of P. aeruginosa, determining the ability of anti-PF antibodies to protect against multiple clinical strains, and examining the presence of anti-PF antibodies in human...
- This Project Grant, valued at $868,776.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to identify the direct regulatory targets of this regulator, called PhAF, under standard laboratory conditions and in clinically relevant...
- This Project Grant award, valued at $160,040.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research conducted by the University of California, San Francisco (UCSF) to investigate how the bacterial pathogen Pseudomonas aeruginosa senses and responds to mechanical deformation of its cell envelope when contacting surfaces. The research aims to further...
- This Project Grant award of $427,625.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to exploit bacteriophages (viruses that infect bacteria) to discover novel anti-biofilm agents. The goal is to improve phage therapy and identify proteins that could be developed as stand-alone therapeutics to treat biofilm-associated infections, which are a particular concern for the opportunistic pathogen Pseudomonas aeruginosa....
- The Project Grant award of $197,646 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to enhance the function of bacteriophages (viruses that attack bacteria) as a potential treatment for antimicrobial resistant bacterial infections. The award recipient, the University of California, San Diego (UCSD), will conduct experimental evolution studies to identify genetic...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $794,849 Project Grant to Cedars-Sinai Medical Center. The grant, awarded on February 25, 2025, supports research to investigate cefiderocol resistance and cross-protection in the bacterium Pseudomonas aeruginosa, which causes lung infections in 44% of cystic fibrosis patients in the U.S. The research aims to understand how...
- This $540,818 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Columbia University on the interdependency of chemical, structural, and physiological heterogeneity in Pseudomonas aeruginosa biofilms. The project aims to investigate how biofilm and infection-site conditions impact P. aeruginosa's use of lactate as a carbon source, and how the bacteria tolerate...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports the "Phage-Seq Phenotyping of the Pseudomonas aeruginosa Surface-ome" research project at Yale University. The $453,629 award, made on July 8, 2025, will utilize a novel "phage-seq" technology to survey the cell surface features of the opportunistic pathogen Pseudomonas aeruginosa....
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $150,000 Project Grant to The Ohio State University to develop novel bacteriophage-based therapies to combat Pseudomonas aeruginosa and Candida spp. dual-species biofilms. The project aims to create combination treatments using antimicrobial peptides and phages, as well as genetically engineer P. aeruginosa phages to produce...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to investigate the role of a Pseudomonas bacteriophage (PF phage) in promoting chronic biofilm lung infections in individuals with cystic fibrosis. The $192,672 award, effective from September 1, 2025 to August 31, 2030, will support research at Stanford University to study how the PF phage mediates iron sequestration and uptake, and how this process affects the growth and pathogenesis of Pseudomonas aeruginosa (PA) bacteria during co-infection with Staphylococcus aureus. The goal is to better understand the mechanisms through which the PF phage can promote PA pathogenesis, which could lead to the identification of novel therapeutic targets for treating chronic PA infections in cystic fibrosis patients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $192.7k | 8/26/25 |